Literature DB >> 11861073

Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses.

Jaafar Bennouna1, Allan Hildesheim, Kazuaki Chikamatsu, William Gooding, Walter J Storkus, Theresa L Whiteside.   

Abstract

To be able to determine the frequencies of helper-type T lymphocyte (Th) precursors specific for viral or tumor-associated antigens, an ELISPOT assay for IL-5 production was developed. The assay reproducibility was first determined using fresh or cryopreserved peripheral blood mononuclear cells (PBMC) obtained from six normal donors and tested for IL-5 production after 48 h stimulation with phytohemagglutinin (PHA). Both inter-assay (within-subject CV=1.6%) and intra-assay (within-subject CV=0.8%) variabilities were found to be acceptable, and the frequencies of IL-5 secreting cells were comparable in cryopreserved and fresh PBMC of the same donors. The presence and frequency of Th precursor cells to viral capsid L1 protein (viral-like particles, VLP-L1) of human papillomavirus type 16 (HPV-16) in PBMC obtained from seven non-immunized donors and two volunteers immunized with VLP-L1 were then evaluated. Using autologous dendritic cells as antigen-presenting cells (APC) for VLP-L1 in direct 48-h ELISPOT assays, the mean frequency of IL-5 secreting CD4+ T cells was found to be <1/10(5) (negative) in normal donors but was 1/2, 436 and 1/3678 in the two volunteers immunized with VLP-L1. The assay is applicable to monitoring of the frequency of antigen-specific T cells in the peripheral circulation of individuals immunized with HPV-derived antigens. To test the assay utility in the assessment of Th tumor-reactive lymphocytes, we also used it to determine the frequency of the wild-type sequence (wt) p53(22-36) peptide-specific, HLA-DR4-restricted T cells in the bulk CD4+ T cell line. This frequency was 1/33. The ELISPOT assay for IL-5 production can be reliably used to measure Th-type responses in a variety of experimental settings.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861073     DOI: 10.1016/s0022-1759(01)00566-x

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  4 in total

1.  Transient inhibition of Th1-type cytokine production by CD4 T cells in hepatitis B core antigen immunized mice is mediated by regulatory T cells.

Authors:  Jessica A Chichester; Mark A Feitelson; Catherine E Calkins
Journal:  Immunology       Date:  2006-06-06       Impact factor: 7.397

2.  Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected].

Authors:  Edward L Nelson; Lari B Wenzel; Kathryn Osann; Aysun Dogan-Ates; Nissa Chantana; Astrid Reina-Patton; Amanda K Laust; Kevin P Nishimoto; Alexandra Chicz-DeMet; Nefertiti du Pont; Bradley J Monk
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

3.  CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer.

Authors:  Kazuaki Chikamatsu; Koichi Sakakura; Goro Takahashi; Atsushi Okamoto; Nobuhiko Furuya; Theresa L Whiteside; Albert B DeLeo; Keisuke Masuyama
Journal:  Cancer Immunol Immunother       Date:  2009-01-28       Impact factor: 6.968

4.  Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.

Authors:  Tomohide Tatsumi; Lisa S Kierstead; Elena Ranieri; Loreto Gesualdo; Francesco P Schena; James H Finke; Ronald M Bukowski; Jan Mueller-Berghaus; John M Kirkwood; William W Kwok; Walter J Storkus
Journal:  J Exp Med       Date:  2002-09-02       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.